TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32473681

Group type: EXPERIMENTAL
Intervention: Azithromycin plus hydroxychloroquine
Number of subjects: 928

Group type: COMPARATOR
Intervention: Residence in Canada
Number of subjects: 928

Group type: COMPARATOR
Intervention: Residence in the US-Midwest
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Age (per 10 years increase)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Former smoker vs never smoked
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Two comorbidities vs none
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: ECOG performance status of 2 or higher vs 0 or 1
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Active cancer (progressing vs remission)
Number of subjects: 928
Study: 32473888

Group type: EXPERIMENTAL
Intervention: Intracoronary imaging-guided pre-dilation, stent sizing, and post-dilation (iPSP)
Number of subjects: 9525

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 9525
Study: 32474892

Group type: EXPERIMENTAL
Intervention: JE-CV (live-attenuated Japanese encephalitis chimeric virus vaccine)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: JE-CV
Number of subjects: 810
Study: 32474893

Group type: EXPERIMENTAL
Intervention: LightPower Taqman real-time PCR method
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Versant 2.0 line probe assay
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combined results of Versant and sequencing
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Versant 2.0 (using 5'UTR and core information)
Number of subjects: 106
Study: 32475029

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 97
Study: 32476053

Group type: EXPERIMENTAL
Intervention: Preterm infants (PTI)
Number of subjects: 29
Study: 32476449

Group type: EXPERIMENTAL
Intervention: Type I collagen matrix plus polyhexamethylene biguanide antimicrobial
Number of subjects: 0
Study: 32476520

Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone therapy with doses adjusted based on creatinine clearance (10 mg for moderate RI, CrCl 30-60 mL/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone therapy
Number of subjects: 0
Study: 32476658

Group type: EXPERIMENTAL
Intervention: Community-based recovery-oriented mental health care (CMHC)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 900
Study: 32476659

Group type: EXPERIMENTAL
Intervention: pre-NDPP (enhanced enrollment)
Number of subjects: 1140

Group type: COMPARATOR
Intervention: NDPP (usual care)
Number of subjects: 1140
Study: 32477003

Group type: EXPERIMENTAL
Intervention: Asthma shared decision making (SDM) toolkit intervention
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Practice facilitation by research nurses
Number of subjects: 10
Study: 32477016

Group type: EXPERIMENTAL
Intervention: RADREMI dosing (SRS doses of 18 Gy for 0-2 cm lesions, 14 Gy for 2.1-3 cm lesions, and 12 Gy for 3.1-4 cm lesions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RADREMI dosing
Number of subjects: 0
Study: 32477853

Group type: COMPARATOR
Intervention: Text messaging outreach alone
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Text messaging with lottery for a 1-in-5 chance of winning $100 after FIT completion
Number of subjects: 281
Study: 32478195

Group type: EXPERIMENTAL
Intervention: Exubera (EXU; insulin human [rDNA origin] Inhalation Powder)
Number of subjects: 1961

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 1961
Study: 32478205

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 781

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 781
Study: 32478814

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nivolumab 0.5 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nivolumab (overall response rate)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nivolumab (1-year progression-free survival)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nivolumab (1-year overall survival)
Number of subjects: 28
Study: 32479189

Group type: EXPERIMENTAL
Intervention: Pembrolizumab with weekly cisplatin-based chemoradiotherapy
Number of subjects: 59
Study: 32479307

Group type: EXPERIMENTAL
Intervention: Barriers to mental health service utilization (MHSU)
Number of subjects: 3358
Study: 32479604

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32479608

Group type: EXPERIMENTAL
Intervention: Artefenomel 200-mg dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Artefenomel 300-mg dose (predicted)
Number of subjects: 8
Study: 32479741

Group type: EXPERIMENTAL
Intervention: Constitutional thinness (CT) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal-weight control group
Number of subjects: 30
Study: 32480059

Group type: EXPERIMENTAL
Intervention: LDL-C < 100 mg/dL (70-99 mg/dL)
Number of subjects: 13623

Group type: EXPERIMENTAL
Intervention: LDL-C < 70 mg/dL
Number of subjects: 13623

Group type: EXPERIMENTAL
Intervention: HbA1c < 7%
Number of subjects: 13623

Group type: COMPARATOR
Intervention: Blood Pressure targets
Number of subjects: 13623
Study: 32480405

Group type: EXPERIMENTAL
Intervention: Whole gene deletions of MKRN3 identified in 2 subjects (13%): Patient A with complete deletion (pubertal onset at 7 years) and Patient B with a larger deletion involving MAGEL2, MKRN3, and NDN (pubertal onset at 5.5 years). Both deletions were paternally inherited.
Number of subjects: 16
Study: 32481274

Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment
Number of subjects: 1000
Study: 32481400

Group type: COMPARATOR
Intervention: TL1A levels in the STEMI group
Number of subjects: 141

Group type: COMPARATOR
Intervention: TL1A levels in the NSTEMI group
Number of subjects: 141

Group type: COMPARATOR
Intervention: hs-CRP and MPO levels in UA, NSTEMI, and STEMI groups
Number of subjects: 141

Group type: COMPARATOR
Intervention: Plasma IL-10 levels in UA, NSTEMI, and STEMI groups
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: TL1A levels in coronary blood vs peripheral blood in STEMI and NSTEMI groups
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Correlation of TL1A levels in coronary and peripheral blood
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: TL1A levels correlation with cTnI, coronary thrombus burden, MACE
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: TL1A levels correlation with IL-10 and Syntax score
Number of subjects: 141
Study: 32482174

Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) technique
Number of subjects: 78
Study: 32482382

Group type: EXPERIMENTAL
Intervention: Water Insecurity (WI)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Interaction of Food Insecurity (FI), Water Insecurity (WI), and HIV
Number of subjects: 183
Study: 32482616

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after one-month dual antiplatelet therapy (DAPT)
Number of subjects: 7185

Group type: COMPARATOR
Intervention: Conventional dual antiplatelet therapy (DAPT)
Number of subjects: 7185

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after one-month DAPT
Number of subjects: 7185
Study: 32482834

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device with Shield technology (PED-Shield)
Number of subjects: 204
Study: 32483359

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 32483557

Group type: EXPERIMENTAL
Intervention: Ebselen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no Ebselen)
Number of subjects: 0
Study: 32483558

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study: 32483680

Group type: EXPERIMENTAL
Intervention: Premixed fast-set tricalcium silicate putty (TotalFil FS putty) as root-end filling material
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 35
Study: 32483745

Group type: EXPERIMENTAL
Intervention: Upper abdominal MR examinations using fat liver acquisition with volume acceleration-flexible (LAVA-Flex) sequence
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Upper abdominal MR examinations using proton density fat fraction (PDFF) maps
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Upper abdominal MR examinations
Number of subjects: 570
Study: 32484413

Group type: EXPERIMENTAL
Intervention: Myocardial global longitudinal strain (GLS) at MRI
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Cox regression analysis of MRI-derived myocardial strain
Number of subjects: 206
Study: 32484435

Group type: EXPERIMENTAL
Intervention: Topical dithranol (anthralin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32484517

Group type: EXPERIMENTAL
Intervention: Obstructive CAD
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Non-obstructive CAD
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Angiographically normal coronary arteries
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Obstructive CAD vs. ACS cohort
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Presence of obstructive CAD
Number of subjects: 1016
Study: 32484552

Group type: EXPERIMENTAL
Intervention: Suvorexant (10 mg for 1 week, titrated to 20 mg for 2 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 32484853

Group type: EXPERIMENTAL
Intervention: Computer-generated STOPP/START recommendations
Number of subjects: 204
Study: 32485203

Group type: EXPERIMENTAL
Intervention: Ketamine (esketamine) treatment for TRD
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Acute psychoactive effects measured by CADSS
Number of subjects: 891
Study: 32486385

Group type: EXPERIMENTAL
Intervention: BI 860585 monotherapy (5-300 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 860585 (40-220 mg/day) with 25 mg/day exemestane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 860585 (80-220 mg/day) with 60-80 mg/m2 paclitaxel
Number of subjects: 0
Study: 32487185

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Recent viral load
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Recent CD4+/CD8+ ratio
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Zidovudine exposure
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate exposure
Number of subjects: 1078
Study: 32487218

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy and radiotherapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CTC status at any timepoint
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CTC patterns following treatment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Detection of CTCs
Number of subjects: 65
Study: 32487229

Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor (LUM/IVA) for 1 month
Number of subjects: 0
Study: 32487237

Group type: EXPERIMENTAL
Intervention: Urine [TIMP-2]*[IGFBP7] measurements at 0h, 6h, 12h, and 24h
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Baseline urine [TIMP-2]*[IGFBP7] in persistent AKI group
Number of subjects: 184

Group type: COMPARATOR
Intervention: Usual clinical variables
Number of subjects: 184
Study: 32487542

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil 35 mg/m²
Number of subjects: 793
Study: 32487569

Group type: EXPERIMENTAL
Intervention: Nivolumab plus gemcitabine and cisplatin
Number of subjects: 32
Study: 32487574

Group type: EXPERIMENTAL
Intervention: Chemotherapy (first-line or third-line)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Questionnaires including EORTC-QLQ-C30, Decisional Conflict Scale, Control Preferences Scale, Quality-Quantity Questionnaire, treatment expectations, EORTC financial toxicity items, Work Ability Index, FACT-G items, Decisional Regret Scale
Number of subjects: 132
Study: 32487642

Group type: EXPERIMENTAL
Intervention: CTC/ctDNA combination assay
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: ctDNA assay
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: CTC assay
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conventional tumor marker
Number of subjects: 111
Study: 32487675

Group type: EXPERIMENTAL
Intervention: Regular strength training
Number of subjects: 118

Group type: COMPARATOR
Intervention: No regular strength training (Control)
Number of subjects: 118
Study: 32488055

Group type: EXPERIMENTAL
Intervention: Tailored treatment strategy (TTS) guided by ex vivo drug sensitivity/resistance profiling (DSRP) and targeted next-generation sequencing (tNGS)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Tailored treatment strategy (TTS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study: 32488236

Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET/CT
Number of subjects: 140
Study: 32488822

Group type: EXPERIMENTAL
Intervention: 3D models of renal cell carcinoma (RCC) with venous tumor thrombus extension (VTE) for surgical simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard images (CT)
Number of subjects: 0
Study: 32488989

Group type: EXPERIMENTAL
Intervention: Sapanisertib 40 mg single dose
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sapanisertib 30 mg once weekly
Number of subjects: 44
Study: 32489644

Group type: EXPERIMENTAL
Intervention: One-day PAH-SYMPACT symptom reporting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seven-day PAH-SYMPACT symptom reporting
Number of subjects: 0
Study: 32489674

Group type: EXPERIMENTAL
Intervention: selfBACK app used for 6 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: selfBACK app usage
Number of subjects: 51
Study: 32489718

Group type: EXPERIMENTAL
Intervention: Algorithm for measuring problem prescription opioid use
Number of subjects: 0
Study: 32489805

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 1423

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 1423

Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment
Number of subjects: 1423

Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs (APD)
Number of subjects: 1423

Group type: EXPERIMENTAL
Intervention: Overall anticoagulation therapy patterns
Number of subjects: 1423
Study: 32490026

Group type: EXPERIMENTAL
Intervention: Combined ACL and anterolateral ligament reconstruction (ACL + ALLR) with hamstring tendon autograft
Number of subjects: 224

Group type: COMPARATOR
Intervention: Isolated ACL reconstruction (ACLR) with bone-patellar tendon-bone (BPTB) autograft
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Combined ACL + ALLR
Number of subjects: 224

Group type: COMPARATOR
Intervention: Isolated ACLR
Number of subjects: 224
Study: 32490343

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 495
Study: 32491152

Group type: EXPERIMENTAL
Intervention: Weight-related information avoidance (WIA) measured via a validated questionnaire
Number of subjects: 87
Study: 32492067

Group type: EXPERIMENTAL
Intervention: LOCUS Bayesian method for multivariate proteomic QTL analysis
Number of subjects: 0
Study: 32492069

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (injection frequency ≤4)
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (injection frequency ≥5)
Number of subjects: 1063
Study: 32492125

Group type: EXPERIMENTAL
Intervention: Diets or supplements containing 30%-155% of VA EARs for 42-90 d in Zambian children
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Diets or supplements containing 30%-155% of VA EARs for 42-90 d in US women
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Diets or supplements containing 30%-155% of VA EARs for 42-90 d in Indonesian women
Number of subjects: 213
Study: 32492942

Group type: EXPERIMENTAL
Intervention: Cilostazol SR capsule (200-mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0

Group type: COMPARATOR
Intervention: DAPT alone (clopidogrel and aspirin)
Number of subjects: 0
Study: 32493044

Group type: EXPERIMENTAL
Intervention: GelrinC
Number of subjects: 56
Study: 32493198

Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate and biopsy
Number of subjects: 40
Study: 32493206

Group type: EXPERIMENTAL
Intervention: Erenumab 140-mg monthly by two subcutaneous 1-mL injections, given every 4 weeks for 12 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 100
Study: 32493217

Group type: EXPERIMENTAL
Intervention: Cardiac MRI protocol added to breast MRI examination
Number of subjects: 0
Study: 32493292

Group type: EXPERIMENTAL
Intervention: Microcalorimetry of synovial fluid
Number of subjects: 107

Group type: COMPARATOR
Intervention: Synovial fluid culture
Number of subjects: 107
Study: 32493367

Group type: EXPERIMENTAL
Intervention: Higher density of physicians (per 1000 people)
Number of subjects: 3588

Group type: EXPERIMENTAL
Intervention: Greater number of nurses (per 1000 people)
Number of subjects: 3588

Group type: COMPARATOR
Intervention: Higher density of hospital beds (per 10,000 people)
Number of subjects: 3588
Study: 32493448

Group type: EXPERIMENTAL
Intervention: Oral vitamin A supplementation (3000 UI/kg/die for 28 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Oral vitamin A supplementation
Number of subjects: 62
Study: 32493484

Group type: EXPERIMENTAL
Intervention: Methylation at 15 cytosine-(phosphate)-guanine sites (CpGs)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Methylation at four (26.7%) CpG sites
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Increased methylation at cg06155341
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Methylation changes related to maternal underweight, preeclampsia, and adult type 2 diabetes
Number of subjects: 301
Study: 32493508

Group type: EXPERIMENTAL
Intervention: Nimble suction device
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cutometer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nimble and Cutometer suction devices
Number of subjects: 60
Study: 32493977

Group type: EXPERIMENTAL
Intervention: Home-based strength and endurance training program (12 weeks pre and 20 weeks post ahSC transplant)
Number of subjects: 6
Study: 32494819

Group type: EXPERIMENTAL
Intervention: Ipsilateral arm movement
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Contralateral arm movement
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Grasping
Number of subjects: 2
Study: 32495011

Group type: EXPERIMENTAL
Intervention: 1TCM model
Number of subjects: 0
Study: 32495282

Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lumpectomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stage 0 patients (N=6)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stage III patients (N=6)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stage I patients (N=25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stage II patients (N=16)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Satisfaction with Decision
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Decision Regret
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: FACT-B quality of life
Number of subjects: 100
Study: 32495314

Group type: EXPERIMENTAL
Intervention: Face-to-face EEG training program followed by e-learning sessions at day 1, day 15, day 30, and day 90.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Face-to-face EEG training program supplemented with e-learning.
Number of subjects: 250
Study: 32496194

Group type: EXPERIMENTAL
Intervention: Activity-dependent modulation in neurogliaform cells
Number of subjects: 0
Study: 32496203

Group type: EXPERIMENTAL
Intervention: mROAD intervention (SMS text message-based program)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham control group (daily sham text messages)
Number of subjects: 72
Study: 32496206

Group type: EXPERIMENTAL
Intervention: Self-assessment web application users with anosmia (n=127,586)
Number of subjects: 3799535

Group type: COMPARATOR
Intervention: Self-assessment web application users without anosmia (n=1,597,289)
Number of subjects: 3799535

Group type: EXPERIMENTAL
Intervention: Participants with anosmia
Number of subjects: 3799535

Group type: EXPERIMENTAL
Intervention: Participants with fever and/or cough
Number of subjects: 3799535
Study: 32496401

Group type: EXPERIMENTAL
Intervention: Neural processing of health information
Number of subjects: 24
Study: 32496541

Group type: EXPERIMENTAL
Intervention: Time from diagnosis to treatment (TDT) of 0 to 5 days
Number of subjects: 2263

Group type: EXPERIMENTAL
Intervention: Time from diagnosis to treatment (TDT) of 6 to 10 days
Number of subjects: 2263

Group type: EXPERIMENTAL
Intervention: Time from diagnosis to treatment (TDT) of 11 to 15 days
Number of subjects: 2263

Group type: EXPERIMENTAL
Intervention: Time from diagnosis to treatment (TDT) of >15 days
Number of subjects: 2263

Group type: EXPERIMENTAL
Intervention: TDT as a continuous variable
Number of subjects: 2263
Study: 32496557

Group type: EXPERIMENTAL
Intervention: Near-infrared photoimmunotherapy (NIR-PIT) using RM1929/ASP1929 (anti-EGFR antibody plus IRDye700DX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIR-PIT
Number of subjects: 0
Study: 32496966

Group type: EXPERIMENTAL
Intervention: technology-based physical activity intervention
Number of subjects: 0
Study: 32497016

Group type: EXPERIMENTAL
Intervention: Online dissemination of the HIV-testing advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dissemination with additional group-level training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition with no intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation fidelity and feasibility assessment through surveys and interviews
Number of subjects: 0
Study: 32497409

Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis (WP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Individualized interval prophylaxis (IP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Modified prophylaxis or episodic treatment
Number of subjects: 120